Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction

Abstract

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia. In past decades, intensive studies on the biology and treatment of this disease have resulted in a remarkably thorough understanding of its pathogenesis and improvement of treatment outcomes. In particular, the introduction of all-trans retinoic acid to conventional chemotherapy improved dramatically the remission and survival rates of APL patients and consequently became the major treatment modality for it. In the last decade, the groundbreaking development of arsenic further improved the survival rate of APL patients. As the most active agent in APL, arsenic directly degrades the PML-RARα fusion transcript, leading to the differentiation and apoptosis of leukemia cells and the potential eradication of APL leukemia-initiating cells (LICs), thus making the disease a potentially curable type of leukemia. More notably, the recent development of oral arsenic compounds may further enhance not only clinical outcomes but also the convenience of patients, which may dramatically change the APL clinical scenario in the near future.

Key words： acute promyelocytic leukemia; arsenic; all-trans retinoic acid; survival

References

1 Rowley J D, Golomb H M, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet, 1977, 1(8010): 549–550

PMID

2 Rousselot P, Hardas B, Patel A, Guidez F, Gäken J, Castaigne S, Dejean A, de Thé H, Degos L, Farzaneh F, .The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene, 1994, 9(2): 545–551

PMID

3 Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 2008, 111(5):2505–2515

4 Huang M E, Ye Y C, Chen S R, Chai J R, Lu J X, Zhoa L, Gu L J, Wang Z Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 1988, 72(2): 567–572

PMID

5 Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood, 1990, 75(11): 2112–2117

PMID

6 Sanz M A, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, Bolufer P, Barragán E, Terol M J, González J D, Colomer D, Chillón C, Rivas C, Gómez T, Ribera J M, Bornstein R, Román J, Calasanz M J, Arias J, Alvarez C, Ramos F, Debén G. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood, 1999, 94(9): 3015–3021

PMID

7 Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Adès L. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol, 2009, 27(16): 2668–2676

PMID

8 Tallman M S, Altman J K. How I treat acute promyelocytic leukemia. Blood, 2009, 114(25): 5126–5135

PMID

9 Shen Z X, Chen G Q, Ni J H, Li X S, Xiong S M, Qiu Q Y, Zhu J, Tang W, Sun G L, Yang K Q, Chen Y, Zhou L, Fang Z W, Wang Y T, Ma J, Zhang P, Zhang T D, Chen S J, Chen Z, Wang Z Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997, 89(9): 3354–3360

PMID

10 Chen G Q, Zhu J, Shi X G, Ni J H, Zhong H J, Si G Y, Jin X L, Tang W, Li X S, Xong S M, Shen Z X, Sun G L, Ma J, Zhang P, Zhang T D, Gazin C, Naoe T, Chen S J, Wang Z Y, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood, 1996, 88(3): 1052–1061

PMID

11 Niu C, Yan H, Yu T, Sun H P, Liu J X, Li X S, Wu W, Zhang F Q, Chen Y, Zhou L, Li J M, Zeng X Y, Yang R R, Yuan M M, Ren M Y, Gu F Y, Cao Q, Gu B W, Su X Y, Chen G Q, Xiong S M, Zhang T D, Waxman S, Wang Z Y, Chen Z, Hu J, Shen Z X, Chen S J. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 1999, 94(10): 3315–3324

PMID

12 Soignet S L, Frankel S R, Douer D, Tallman M S, Kantarjian H, Calleja E, Stone R M, Kalaycio M, Scheinberg D A, Steinherz P, Sievers E L, Coutré S, Dahlberg S, Ellison R, Warrell R P Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol, 2001, 19(18): 3852–3860

PMID

13 Mathews V, George B, Lakshmi K M, Viswabandya A, Bajel A, Balasubramanian P, Shaji R V, Srivastava V M, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood, 2006, 107(7): 2627–2632

PMID

14 Mathews V, George B, Chendamarai E, Lakshmi K M, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji R V, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol, 2010, 28(24): 3866–3871

PMID

15 Ghavamzadeh A, Alimoghaddam K, Ghaffari S H, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol, 2006, 17(1): 131–134

PMID

16 Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y, Li X, Han X, Zhou J, Liu P. Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide-an analysis of 242 cases. Chin J Hematol, 2000, 21(2): 67–70

17 Zhou G B, Zhang J, Wang Z Y, Chen S J, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci, 2007, 362(1482): 959–971

PMID

18 Lallemand-Breitenbach V, Guillemin M C, Janin A, Daniel M T, Degos L, Kogan S C, Bishop J M, de Thé H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med, 1999, 189(7): 1043–1052

PMID

19 Jing Y, Wang L, Xia L, Chen G Q, Chen Z, Miller W H, Waxman S. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood, 2001, 97(1): 264–269

PMID

20 Raffoux E, Rousselot P, Poupon J, Daniel M T, Cassinat B, Delarue R, Taksin A L, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand J P, de Thé H, Degos L, Hermine O, Dombret H. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol, 2003, 21(12): 2326–2334

PMID

21 Shen Z X, Shi Z Z, Fang J, Gu B W, Li J M, Zhu Y M, Shi J Y, Zheng P Z, Yan H, Liu Y F, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang Z Y, Chen S J, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA, 2004, 101(15): 5328–5335

PMID

22 Hu J, Liu Y F, Wu C F, Xu F, Shen Z X, Zhu Y M, Li J M, Tang W, Zhao W L, Wu W, Sun H P, Chen Q S, Chen B, Zhou G B, Zelent A, Waxman S, Wang Z Y, Chen S J, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA, 2009, 106(9): 3342–3347

PMID

23 Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood, 2006, 107(9): 3469–3473

PMID

24 Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol, 2009, 27(4): 504–510

PMID

25 Powell B L, Moser B, Stock W, Gallagher R E, Willman C L, Stone R M, Rowe J M, Coutre S, Feusner J H, Gregory J, Couban S, Appelbaum F R, Tallman M S, Larson R A. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 2010, 116(19): 3751–3757

PMID

26 Sanz M A, Grimwade D, Tallman M S, Lowenberg B, Fenaux P, Estey E H, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett A K, Lo-Coco F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2009, 113(9): 1875–1891

PMID

27 Zhu J, Lallemand-Breitenbach V, de Thé H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene, 2001, 20(49): 7257–7265

PMID

28 Zhu J, Zhou J, Peres L, Riaucoux F, Honoré N, Kogan S, de Thé H. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell, 2005, 7(2): 143–153

PMID

29 Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honoré N, Doubeikovsky A, Duprez E, Pandolfi P P, Puvion E, Freemont P, de Thé H. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med, 2001, 193(12): 1361–1371

PMID

30 Zhang X W, Yan X J, Zhou Z R, Yang F F, Wu Z Y, Sun H B, Liang W X, Song A X, Lallemand-Breitenbach V, Jeanne M, Zhang Q Y, Yang H Y, Huang Q H, Zhou G B, Tong J H, Zhang Y, Wu J H, Hu H Y, de Thé H, Chen S J, Chen Z. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 2010, 328(5975): 240–243

PMID

31 Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin M C, de Thé H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res, 2009, 15(20): 6321–6326

PMID

32 Wang J C, Dick J E. Cancer stem cells: lessons from leukemia. Trends Cell Biol, 2005, 15(9): 494–501

PMID

33 Grignani F, Ferrucci P F, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, .The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell, 1993, 74(3): 423–431

PMID

34 Du C, Redner R L, Cooke M P, Lavau C. Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes. Blood, 1999, 94(2): 793–802

PMID

35 Nasr R, Guillemin M C, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi P P, Rochette-Egly C, Zhu J, de Thé H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med, 2008, 14(12): 1333–1342

PMID

36 Delva L, Cornic M, Balitrand N, Guidez F, Micléa J M, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L, .Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood, 1993, 82(7): 2175–2181

PMID

37 Zheng X, Seshire A, Rüster B, Bug G, Beissert T, Puccetti E, Hoelzer D, Henschler R, Ruthardt M. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica, 2007, 92(3): 323–331

PMID

38 Kogan S C. Curing APL: differentiation or destruction? Cancer Cell, 2009, 15(1): 7–8

PMID

39 Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan D E, Teruya-Feldstein J, Pandolfi P P. PML targeting eradicates quiescent leukaemia-initiating cells. Nature, 2008, 453(7198): 1072–1078

PMID

40 Luesink M, Pennings J L, Wissink W M, Linssen P C, Muus P, Pfundt R, de Witte T J, van der Reijden B A, Jansen J H. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood, 2009, 114(27): 5512–5521

PMID

41 Tallman M S, Andersen J W, Schiffer C A, Appelbaum F R, Feusner J H, Ogden A, Shepherd L, Rowe J M, François C, Larson R S, Wiernik P H. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood, 2000, 95(1): 90–95

PMID

42 Ng J C, Wang J, Shraim A. A global health problem caused by arsenic from natural sources. Chemosphere, 2003, 52(9): 1353–1359

PMID

43 Ficker E, Kuryshev Y A, Dennis A T, Obejero-Paz C, Wang L, Hawryluk P, Wible B A, Brown A M. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol, 2004, 66(1): 33–44

PMID

44 Kojima C, Ramirez D C, Tokar E J, Himeno S, Drobná Z, Stýblo M, Mason R P, Waalkes M P. Requirement of arsenic biomethylation for oxidative DNA damage. J Natl Cancer Inst, 2009, 101(24): 1670–1681

PMID

45 Hughes M F. Arsenic methylation, oxidative stress and cancer—is there a link? J Natl Cancer Inst, 2009, 101(24): 1660–1661

PMID

46 Lu D P, Qiu J Y, Jiang B, Wang Q, Liu K Y, Liu Y R, Chen S S. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood, 2002, 99(9): 3136–3143

PMID

47 The Cooperation Group of Phase II Clinical Trial of Compound Huangdai Tablet. Phase II clinical trial of compound Huangdai tablet in newly diagnosed acute promyelocytic leukemia. Chin J Hematol, 2006, 27(12): 801–804

48 Sun F, Chen N N, Cheng Y B. Compound realgar and natural indigo tablets in treatment of acute promyelocytic leukemia: a summary of experience in 204 cases. Zhong Xi Yi Jie He Xue Bao, 2008, 6(6): 639–642

PMID

49 Au W Y, Kumana C R, Kou M, Mak R, Chan G C, Lam C W, Kwong Y L. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood, 2003, 102(1): 407–408

PMID

50 Siu C W, Au W Y, Yung C, Kumana C R, Lau C P, Kwong Y L, Tse H F. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood, 2006, 108(1): 103–106

PMID